Background: Although prostate cancer releases more prostate-specific antigen (PSA) per unit of prostate volume (PV), data are limited regarding the association between intravesical prostatic protrusion (IPP) and the PSA level. Objectives: The study aim was to evaluate the IPP effect in patients with benign prostatic hyperplasia. Method: This study included patients with (n = 119) and without (n = 121) IPP. The age, International Prostate Symptom Score (IPSS), PSA level, maximum and average flow rates, PV, hematuria, urinary retention, and post-void residual (PVR) volume were compared between the 2 groups. Results: The mean ages were similar between the 2 groups (66.56 ± 8.67 and 66.92 ± 8.7 years, respectively, p = 0.747), and there were no statistically significant differences in the IPSS, maximum and average flow rates, hematuria, PVR volume, and urinary retention means (p > 0.05). However, the IPP patients had lower total PSA (tPSA) and free PSA (fPSA) levels than those without IPP (3.55 [4.18] vs. 5.26 [5.24] ng/mL, p = 0.013 and 0.7 [1.09] vs. 1.05 [1.23] ng/mL, p = 0.029, respectively). Moreover, there were strong positive correlations between the IPP grade and the tPSA and fPSA levels (r = 0.262, p = 0.001 and r = 0.254, p = 0.002 respectively). Conclusions: This study demonstrated that IPP results in a decreased PSA level, even with a higher PV.

Keywords:
Benign prostatic hyperplasia, Prostate specific antigen, Prostate, Ultrasound, Uroflowmetry, Intravesical prostatic protrusion
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age.
J Urol
. 1984 Sep;132(3):474–9.
2.
Roehrborn CG. Pathology of benign prostatic hyperplasia.
Int J Impot Res
. 2008 Dec;20(S3 Suppl 3):S11–8.
3.
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Eur Urol
. 2015 Jun;67(6):1099–109.
4.
Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.
Eur Urol
. 2000 Nov;38(5):563–8.
5.
Kang M, Kim M, Choo MS, Bae J, Ku JH, Yoo C, et al. Association of high bladder neck elevation with urodynamic bladder outlet obstruction in patients with lower urinary tract symptoms and benign prostatic hyperplasia.
Urology
. 2014 Dec;84(6):1461–6.
6.
Lee SW, Cho JM, Kang JY, Yoo TK. Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion.
Korean J Urol
. 2010 Oct;51(10):694–9.
7.
Tan YH, Foo KT. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention.
J Urol
. 2003 Dec;170(6 Pt 1):2339–41.
8.
Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
J Urol
. 2007 Aug;178(2):573–7; discussion 577.
9.
Løvvik A, Yaqub S, Oustad H, Sand TE, Nitti VW. Can noninvasive evaluation of benign prostatic obstruction be optimized?
Curr Opin Urol
. 2012 Jan;22(1):1–6.
10.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
N Engl J Med
. 1987 Oct;317(15):909–16.
11.
Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction.
BJU Int
. 2003 Mar;91(4):371–4.
12.
Kalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MB, et al. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement.
Urology
. 2016 Feb;88:161–5.
13.
Suzuki T, Otsuka A, Ozono S. Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Int J Urol
. 2016 Nov;23(11):929–33.
14.
Kang DH, Lee JY, Hah YS, Chung DY, Lee DH, Cho KS. Correlation of prostatic urethral angle with the severity of urinary symptom and peak flow rate in men with small prostate volume.
PLoS One
. 2014 Aug;9(8):e104395.
15.
Lim KB, Ho H, Foo KT, Wong MY, Fook-Chong S. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction.
Int J Urol
. 2006 Dec;13(12):1509–13.
16.
Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement.
Urology
. 2007 Dec;70(6):1096–9.
17.
Nose H, Foo KT, Lim KB, Yokoyama T, Ozawa H, Kumon H. Accuracy of two noninvasive methods of diagnosing bladder outlet obstruction using ultrasonography: intravesical prostatic protrusion and velocity-flow video urodynamics.
Urology
. 2005 Mar;65(3):493–7.
18.
Lieber MM, Jacobson DJ, McGree ME, St Sauver JL, Girman CJ, Jacobsen SJ. Intravesical prostatic protrusion in men in Olmsted County, Minnesota.
J Urol
. 2009 Dec;182(6):2819–24.
19.
Doo CK, Uh HS. Anatomic configuration of prostate obtained by noninvasive ultrasonography can predict clinical voiding parameters for determining BOO in men with LUTS.
Urology
. 2009 Feb;73(2):232–6.
20.
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Urology
. 1999 Mar;53(3):581–9.
21.
Xu D, Yu Y, Zhu Y, Huang T, Chen Y, Qi J. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer.
Pathol Oncol Res
. 2014 Apr;20(2):439–43.
22.
Lee LS, Sim HG, Lim KB, Wang D, Foo KT. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment.
Int J Urol
. 2010 Jan;17(1):69–74.
23.
Park HY, Lee JY, Park SY, Lee SW, Kim YT, Choi HY, et al. Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia.
Korean J Urol
. 2012 Feb;53(2):92–7.
24.
Shin SH, Kim JW, Kim JW, Oh MM, Moon G. Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction.
Korean J Urol
. 2013 Jun;54(6):369–72.
25.
Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
Urology
. 2006 Aug;68(2):352–6.
26.
Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
Eur Urol
. 2003 Dec;44(6):695–700.
27.
Park DS, Hong JY, Hong YK, Lee SR, Hwang JH, Kang MH, et al. Correlation between serum prostate specific antigen level and prostate volume in a community-based cohort: large-scale screening of 35,223 Korean men.
Urology
. 2013 Dec;82(6):1394–9.
28.
Becker B, Buttice S, Magno C, Gross AJ, Netsch C. Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up.
Urol Int
. 2018;100(1):105–11.
29.
Liu Q, Zhu Y, Liu J, Qi J, Kang J. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
Int Urol Nephrol
. 2017 Mar;49(3):399–404.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.